Folinic acid + 5-Fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of ‘GISCAD’ (Italian Group for the Study of Digestive Tract Cancer)
Authors:
- 1 October 1991
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 2 (9) , 673-679
Abstract
In a multicentre Phase III trial, 182 patients were randomized to either folinic acid (FA) (200 mg/sqm i.v. × 5 days) + 5-fluorouracil (5-FU) (400 mg/sqm i.v. in 15' × 5 days) every 4 weeks (Arm A), or to 5-FU one at the same dosage (Arm B). Response rates were 20.6% (Arm A) and 10% (Arm B) with a significant (p = 0.046) advantage for FA + 5-FU. Median time to progression (6 and 6 months) and overall survival (11.5 and 11 months) were similar in the 2 groups of patients, while neither treatment was effective in reducing pain or improving performance status. Univariate analysis showed that no prognostic factors other than treatment influenced response, although survival was affected by the number and site of metastases, performance status, and the presence and degree of pain. Toxicity was acceptable and lower in comparison with other Phase II-III trials, with no significant difference between the 2 arms. However, in individual patients, grade 3-4 side effects (mainly stomatitis and diafrrhoea) were observed, particularly in patients receiving FA: this led to interruption of the treatment in 7 cases. The superiority, in terms of objective response, of FA + 5-FU over 5-FU alone would seem to justify a large-scale evaluation of this combination in the adjuvant setting. Further improvements in relation to advanced disease (i.e, modifications to the schedule and/or introduction of other modulators) are warranted.Keywords
This publication has 12 references indexed in Scilit:
- The calculation of received dose intensity.Journal of Clinical Oncology, 1990
- Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group.Journal of Clinical Oncology, 1989
- Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.Journal of Clinical Oncology, 1989
- The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group.Journal of Clinical Oncology, 1989
- A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma.Journal of Clinical Oncology, 1988
- A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.Journal of Clinical Oncology, 1987
- Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.Journal of Clinical Oncology, 1986
- Graphic representation of painPain, 1976
- Regression Models and Life-TablesJournal of the Royal Statistical Society Series B: Statistical Methodology, 1972
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958